

XmAb 5592

Cat. No.:	HY-P99381
CAS No.:	1221901-33-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) ^[1] .								
In Vitro	<p>XmAb 5592 (0-1000 ng/mL) enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) against multiple myeloma (MM) cells. XmAb 5592 significantly augments ADCC relative to the IgG1 analog against all cell lines ranged from 5-27 ng/mL, also augments antibody dependent cellular phagocytosis (ADCP) by macrophages^[1].</p> <p>XmAb 5592 (0-10000 ng/mL) induces strong MM cell lysis by degranulation of NK cells even in the presence of bone marrow stromal cells (BMSCs)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>XmAb 5592 (0.3-9 mg/kg; i.p.; twice weekly for 7 doses; SCID mice with palpable RPMI8226 tumors) inhibits tumor growth in mice bearing human MM xenografts via FcγR-dependent mechanisms^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="344 1365 1515 1602"> <tr> <td>Animal Model:</td> <td>SCID mice with palpable RPMI8226 tumors^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.3, 3 and 9 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; twice weekly for 7 doses</td> </tr> <tr> <td>Result:</td> <td>Inhibited growth of established myeloma tumors in vivo and eradicates tumors in mice.</td> </tr> </table>	Animal Model:	SCID mice with palpable RPMI8226 tumors ^[1]	Dosage:	0.3, 3 and 9 mg/kg	Administration:	Intraperitoneal injection; twice weekly for 7 doses	Result:	Inhibited growth of established myeloma tumors in vivo and eradicates tumors in mice.
Animal Model:	SCID mice with palpable RPMI8226 tumors ^[1]								
Dosage:	0.3, 3 and 9 mg/kg								
Administration:	Intraperitoneal injection; twice weekly for 7 doses								
Result:	Inhibited growth of established myeloma tumors in vivo and eradicates tumors in mice.								

REFERENCES

[1]. Tai YT, et, al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Mar 1;119(9):2074-82.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA